Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and …
Objective To evaluate pathological complete response as a surrogate endpoint for disease-
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer
M Kaufmann, G Von Minckwitz, EP Mamounas… - Annals of surgical …, 2012 - Springer
The use of neoadjuvant systemic therapy (NST) for the treatment of primary breast cancer
has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s …
has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s …
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
M Kaufmann, GN Hortobagyi, A Goldhirsch… - Journal of Clinical …, 2006 - ascopubs.org
Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced
breast cancer and a standard option for primary operable disease. Because of new …
breast cancer and a standard option for primary operable disease. Because of new …
Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 …
A Berruti, V Amoroso, F Gallo, V Bertaglia… - Journal of clinical …, 2014 - ascopubs.org
Purpose To assess the role of pathologic complete response (pCR) after neoadjuvant
therapy as surrogate end point of disease-free survival (DFS) and overall survival (OS) in …
therapy as surrogate end point of disease-free survival (DFS) and overall survival (OS) in …
Preoperative chemotherapy for women with operable breast cancer
JH van der Hage, CJH van de Velde… - Cochrane database …, 2007 - cochranelibrary.com
Background Currently, preoperative chemotherapy is the standard of care in locally
advanced breast cancer to achieve local tumour downsizing in order to make surgery …
advanced breast cancer to achieve local tumour downsizing in order to make surgery …
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
JR Gralow, HJ Burstein, W Wood… - Journal of Clinical …, 2008 - ascopubs.org
Purpose To review the state of the science with respect to preoperative systemic therapy and
pathologic assessment in operable breast cancer. Methods This article reviews data …
pathologic assessment in operable breast cancer. Methods This article reviews data …
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
M De Laurentiis, G Cancello, D D'Agostino… - Journal of clinical …, 2008 - ascopubs.org
Purpose We conducted a meta-analysis of randomized trials that evaluated the efficacy of
incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC). We …
incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC). We …
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies
S Murray, E Briasoulis, H Linardou, D Bafaloukos… - Cancer treatment …, 2012 - Elsevier
BACKGROUND: Taxanes are established in the treatment of metastatic breast cancer (MBC)
and early breast cancer (EBC) as potent chemotherapy agents. However, their therapeutic …
and early breast cancer (EBC) as potent chemotherapy agents. However, their therapeutic …
[HTML][HTML] Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer
Materials and methods: With this purpose, a descriptive cross-sectional study was
developed on 110 breast cancer patients who were treated with docetaxel, epirubicin, and …
developed on 110 breast cancer patients who were treated with docetaxel, epirubicin, and …